

Smoking, vaping, and comorbidities associated with adverse COVID-19 outcomes

Tabaquismo, vapeo y comorbilidades asociadas a desenlaces adversos de COVID-19

Ileri Thirión-Romero¹, Sebastián Rodríguez-Llamazares², Leonor García-Gómez¹, Jennifer Osio-Echánove¹, Andrea Hernández-Pérez¹, and Rogelio Pérez-Padilla^{1*}

¹Department of Physiology and Respiratory Therapy, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico;

²Department of Medicine, Division of Respiriology and Sleep Medicine, Queen's University, Kingston, Canada

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the critical role of individual factors, such as pre-existing comorbidities and risk behaviors, in the clinical progression of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This article reviews current evidence on the impact of smoking, vaping, and various comorbidities on adverse outcomes associated with the infection. The ACE2 (angiotensin-converting enzyme 2) receptor and its overexpression in smokers may facilitate viral entry and worsen clinical outcomes. The shared pathophysiological mechanisms between nicotine exposure and COVID-19 progression are analyzed, including oxidative stress, immune dysfunction, and systemic inflammation. Common comorbidities such as hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), cardiovascular disease, chronic kidney disease, obesity, and neurovascular conditions are associated with an increased risk of hospitalization, admission to intensive care units, post-COVID-19 syndrome, and mortality and may also be related to persistent symptoms after the acute phase. The coexistence of comorbidities and exposure to nicotine-containing products represents a modifiable risk factor that warrants urgent attention. Strengthening prevention strategies, clinical monitoring, and tobacco cessation promotion are recommended as key measures to reduce disease burden among vulnerable populations.

Keywords: Tobacco. E-cigarette. COVID-19. SARS-CoV-2. Comorbidities.

Resumen

La pandemia de enfermedad por coronavirus 2019 (COVID-19) ha puesto en evidencia el papel determinante de factores individuales, como comorbilidades preexistentes y conductas de riesgo, en la evolución clínica de los pacientes infectados por coronavirus 2 del síndrome respiratorio agudo grave (SARS-CoV-2). Este artículo revisa la evidencia actual sobre el impacto del tabaquismo, el vapeo y diversas comorbilidades en los desenlaces adversos asociados a la infección. El receptor viral ECA2 (enzima convertidora de la angiotensina 2) y su sobreexpresión en personas fumadoras podría facilitar la entrada viral y agravar el cuadro clínico. Asimismo, se analizan los mecanismos fisiopatológicos comunes entre la exposición a nicotina y la progresión de la COVID-19, incluyendo el estrés oxidativo, la disfunción inmunitaria y la inflamación sistémica. Varias comorbilidades frecuentes se asocian con mayor riesgo de hospitalización, ingreso a cuidados intensivos, síndrome

*Correspondence:

Rogelio Pérez-Padilla
E-mail: perezpad@gmail.com

Date of reception: 23-06-2025
Date of acceptance: 07-07-2025
DOI: 10.24875/NCTE.M25000016

Available online: 12-05-2026
Neumol Cir Torax (Eng). 2025;84(2):109-115
www.revistanct.org.mx

post-COVID-19 y mortalidad como la hipertensión, la diabetes mellitus, la enfermedad pulmonar obstructiva crónica (EPOC), la enfermedad cardiovascular, la insuficiencia renal crónica, obesidad y enfermedades neurovasculares, y pueden relacionarse también con la persistencia de síntomas tras la fase aguda. Se concluye que la coexistencia de comorbilidades y la exposición a productos con nicotina representan factores de riesgo modificables, cuya atención debe ser prioritaria. Se recomienda reforzar las estrategias de prevención, vigilancia clínica y promoción de la cesación tabáquica como elementos clave para reducir la carga de enfermedad en poblaciones vulnerables.

Palabras clave: Tabaquismo. Cigarro electrónico. COVID-19. SARS-CoV-2. Comorbilidades.

Introduction

Various comorbidities and risk factors have been associated with a higher likelihood of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and with the development of severe forms of COVID-19 (Table 1). In addition, these factors have been observed to contribute to the persistence of symptoms after acute infection, known as long COVID-19 and post-COVID-19 syndrome^{1,2}.

The presence of comorbidities not only increases the risk of infection but also the likelihood of obtaining a positive PCR (polymerase chain reaction) test and developing antibodies, even in the absence of symptoms. Depending on the type of comorbidity, the risk may vary: symptomatic infection without pneumonia, need for hospitalization, mechanical ventilation, or death. Likewise, certain comorbidities may favor the development of additional complications such as thromboembolism or acute kidney injury. It is estimated that approximately 40% of individuals who develop SARS-CoV-2 infection have at least 1 comorbidity, and among those who die, around 74% had a preexisting condition¹.

Pathophysiology of SARS-CoV-2 infection

SARS-CoV-2 is a virus that infects alveolar epithelial cells through the angiotensin-converting enzyme 2 (ACE2) pathway. This ACE2 receptor acts as a binding site for the spike (S) protein of the SARS virus (SARS-CoV). The modified S protein of SARS-CoV-2 has a significantly higher affinity for ACE2, with a binding probability 10 to 20 times greater than that observed with the S protein of the earlier SARS-CoV.

ACE2 is widely distributed in various organs, including the heart, vascular system, kidneys, lungs, and colon, among others. During SARS-CoV-2 infection, ACE2 expression in alveolar epithelial cells decreases, leading to increased levels of angiotensin II. This increase promotes vascular smooth muscle contraction, cellular proliferation, inflammation, and endothelial dysfunction^{3,4}.

In addition, viral replication produces an imbalance in the immune response mediated by T helper type 1 and type 2 lymphocytes, which may trigger the so-called “cytokine storm”³.

Comorbidities and increased risk of adverse events

Many of the comorbidities observed in patients with COVID-19 are characterized by chronic inflammatory processes. For example, patients with cardiovascular and cerebrovascular diseases exhibit persistent vascular damage, whereas those with COPD develop alveolar epithelial deterioration. These factors, when combined with the acute process of SARS-CoV-2 infection, significantly increase the risk of complications³.

The development of complications during SARS-CoV-2 infection depends on various factors, including the type of comorbidity, age, type of medications used (eg, nonsteroidal anti-inflammatory drugs [NSAIDs] and nephrotoxic agents, among others), viral load, and the integrity of host defense mechanisms.

Most comorbidities create a state in which defense mechanisms are impaired⁵.

The integrity of the respiratory mucosa, the proper functioning of the mucociliary mechanism, and innate defense systems in general constitute the first line of protection in previously exposed individuals. These innate mechanisms may be reinforced by adaptive immunity through antibodies and lymphocytes previously sensitized by vaccination, prior infection, or exogenous antibody administration. In cases of immunosuppression, greater viral replication during the early stages of infection is expected, which may translate into increased tissue damage and more severe clinical complications.

Age has been identified as one of the most important predictive factors for severe complications and mortality from COVID-19⁶; as age increases, the number of comorbidities rises and outcomes worsen. However, several statistical models have allowed differentiation between the independent effects of age and comorbidities.

Table 1. Comorbidities and risk factors associated with SARS-CoV-2 infection

Comorbidity/risk factor	Positive COVID-19 diagnosis	Severe disease	Mortality
Sex M:F ^{1,2-5}	-	-	2.8:1.7 OR, 1.69 (1.65-1.73)
Diabetes mellitus (prevalence, %) ^{1,3-5}	9-65%	16.8-29.1% OR, 3.12 95% CI: 1.0-9.75	24.9% RR, 1.95 (1.41-2.49)
Cerebrovascular disease: Systemic arterial hypertension ^{1,2-5} (prevalence, %)	8.0% 14.3% 95% CI: 6.6-28.42	26.46% 47.65% OR, 1.97 95% CI: 1.40-2.77	RR, 2.14 (1.66-2.63) ² 25.2% 47.9%
Cerebrovascular disease ²			RR, 2.43 (2.15-2.72) ²
Respiratory diseases: COPD ^{1,3-5} (prevalence, %)	3.7%	17.28-25.4% OR, 6.42 95% CI: 2.44-16.9	RR, 1.98 (1.48-2.47) ² 10.9%
Obesity ^{6,7}	OR, 1.50 95% CI: 1.37-1.63	OR, 1.54 95% CI: 1.33-1.78	OR, 1.14 95% CI: 1.04-1.26
Deep vein thrombosis ⁸ Pulmonary embolism ¹¹ (prevalence, %)	30% 18%	-	-
Acute kidney injury ⁹ (prevalence, %)	10.6%	-	OR, 11.05 95% CI: 9.13-13.36
Cancer ²			RR, 1.84 (1.24-2.43)
Smoking ^{1,3,4,5,10}	-	OR, 1.96 95% CI: 1.36-2.83	OR, 1.18 (1.13-1.22) ²
Current smokers Former smokers	6.98% -	- OR, 3.29 95% CI: 1.51-7.18	-

COVID-19, coronavirus disease 2019; COPD, chronic obstructive pulmonary disease; 95% CI, 95% confidence interval; OR, odds ratio; RR, relative risk; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; PE, pulmonary embolism.

The rate of SARS-CoV-2 infection triples after 18 years of age; the hospitalization rate increases up to 15-fold after 40 years of age; and mortality is 45 times higher in individuals > 30 years³.

In databases such as the Mexican COVID-19 registry, an additive effect of comorbidities has been observed, meaning that the number of comorbidities is a strong predictor of mortality (Fig. 1). For example, patients with severe disease more frequently had at least 1 comorbidity: hypertension (odds ratio [OR], 2.36), respiratory diseases (OR, 2.46), and cardiovascular diseases (OR, 3.42)⁶⁻¹⁰. Similarly, age has been associated with a higher risk of developing post-COVID-19 syndrome, with an OR of 1.21 (95% CI, 1.11-1.33)¹¹.

Male sex has been associated with a higher risk of requiring admission to intensive care units, with an OR of 1.55 (95% CI, 1.02-2.36)¹², as well as an increased risk of mortality³. Women appear to have lower susceptibility to severe SARS-CoV-2 infection, attributed to the

influence of sex hormones, which play an important role in both innate and adaptive immunity³. However, this trend is reversed in post-COVID-19 syndrome, where female sex has shown a higher risk, with an OR of 1.56 (95% CI, 1.41-1.73) according to a systematic review¹¹.

The association between obesity and SARS-CoV-2 infection, as well as its negative impact on clinical prognosis, has been documented in several studies^{2,5,13}. Obesity increases the risk of obtaining a positive PCR test for SARS-CoV-2, with an OR of 1.50 (95% CI, 1.37-1.63); moreover, the higher the body mass index (BMI), the greater the probability of a positive result. Similarly, obesity has been associated with a higher risk of hospitalization and intensive care unit admission, with ORs of 1.54 (95% CI, 1.33-1.78) and 1.48 (95% CI, 1.24-1.77), respectively, and a higher risk of death (OR, 1.14; 95% CI, 1.04-1.26)⁸.

Coronary artery disease, stroke, and heart failure have shown an incidence 2 to 3 times higher in patients




Figure 1. Association between case fatality and number of comorbidities in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Mexico.

requiring intensive care unit admission, and mortality rates of up to 10.5% have been reported in individuals with these comorbidities^{1,5}.

Similarly, the presence of diabetes mellitus has been associated with a significant increase in mortality among patients with SARS-CoV-2 infection, as shown in a recent meta-analysis reporting a relative risk (RR) of 1.95 (95% CI, 1.41-2.49). In the case of pulmonary diseases, a similar pattern has been observed, with a higher risk of mortality (RR, 1.98; 95% CI, 1.48-2.47)².

Certain comorbidities have been identified as increasing the risk of developing more severe SARS-CoV-2 infection, with high and consistent levels of evidence. These include chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart failure, coronary artery disease, cardiomyopathies, obesity, pregnancy, smoking, solid organ transplantation, and type 2 diabetes mellitus^{1,8}. On the other hand, comorbidities associated with a higher risk of infection after contact with a confirmed case include systemic hypertension, chronic respiratory diseases, diabetes, and cerebrovascular diseases⁹.

Among the comorbidities described as risk factors for developing post-COVID-19 syndrome are ischemic heart disease, immunosuppression, diabetes, COPD, anxiety, depression, asthma, and having required hospitalization during the acute infection. On the other hand, a protective factor for the development of post-COVID-19 syndrome is having received two doses of COVID-19 vaccination¹¹.

The incidence rate of deep vein thrombosis also increases in the context of SARS-CoV-2 infection and has been associated primarily with advanced age and higher BMI. This phenomenon is largely attributed to thrombophilia due to dysregulation of the hemostatic system, as well as prolonged immobilization in many patients. Pathologic studies have demonstrated a higher prevalence of thrombosis and microangiopathy in patients with SARS-CoV-2 infection vs those with H1N1 influenza¹⁴.

Chronic kidney disease represents a significant risk factor that more strongly influences mortality than the total number of comorbidities present^{5,15,16}. Several systematic reviews have estimated an increased risk of

mortality in patients with renal involvement². The mechanism of injury is attributed in part to direct damage to intrinsic renal cells, as SARS-CoV-2 acts as a cytopathic virus. Epithelial cells of the renal proximal tubules exhibit high expression of the ACE2 receptor, which facilitates viral binding to this cell type and contributes to greater renal injury¹⁵.

Smoking, vaping, and the presence of comorbidities

Nicotine use, regardless of its form – whether through combustible cigarettes, electronic cigarettes (vaping devices), or heated tobacco products – represents a significant risk to the pulmonary and cardiovascular systems¹⁷. Nicotine administration, through either combustible cigarettes or electronic devices, has been shown to increase systolic and diastolic blood pressure, peripheral pulse pressure, and heart rate¹⁸. Over the long term, these changes induced by continuous nicotine exposure may lead to permanent cardiovascular dysfunction, particularly in predisposed individuals or those with preexisting diseases.

Various mechanisms associated with tobacco use contribute to these effects, including increased heart rate and myocardial contractility, inflammation, endothelial dysfunction, thrombus formation, and reduced serum levels of high-density lipoprotein cholesterol (HDL-C). Moreover, these alterations increase oxidative stress and systemic inflammation¹⁹. In the case of electronic cigarette or vaping device use, an additional acute inflammatory response is triggered by several additives present in these devices, such as propylene glycol, glycerin, and flavoring agents.

Accordingly, the association between smoking and the development of cardiovascular diseases has been widely described in the literature^{19,20}, and similar findings have been reported with the use of electronic devices²¹. Moreover, recent studies show that reducing tobacco consumption – and even more so, complete smoking cessation – has an impact on lowering the risk of comorbidities and death^{20,22,23}.

Smoking, vaping, and COVID-19

Various cellular signaling pathways and genes have been identified that are affected both by nicotine use – whether through conventional cigarettes, electronic cigarettes, or other forms of nicotine delivery – and by SARS-CoV-2 infection and disease progression²⁴. ACE2 receptors are upregulated in the airway epithelium of

smokers, especially on the surface of type II pneumocytes²⁵, with greater ACE gene expression observed in samples from smokers compared with never-smokers, and increased ACE2 receptor expression in the lungs of smokers with COPD as demonstrated by immunohistochemistry²⁶. The previously described loss of homeostasis and the facilitated binding of the SARS-CoV-2 spike protein to epithelium due to increased ACE2 receptor expression confer a higher risk of developing viral infection such as SARS-CoV-2¹⁰.

A retrospective case-control study based on electronic health records of 73,099,850 patients, of whom 12,030 had confirmed COVID-19, reported that individuals with a recent diagnosis of substance use disorder had a significantly higher risk of contracting COVID-19 (adjusted OR, 8.699; 95% CI, 8.411-8.997; $p < 10^{-30}$), particularly in the case of tobacco use (adjusted OR, 8.222; 95% CI, 7.925-8.530; $p < 10^{-30}$)²⁷. Furthermore, a meta-analysis demonstrated a higher risk of mortality among individuals with a history of smoking compared with never-smokers (OR, 1.18; 95% CI, 1.13-1.22)², as well as a greater risk of developing post-COVID-19 syndrome among smokers compared with never-smokers¹¹.

In particular, dual users – those who use both conventional tobacco and electronic cigarettes – have up to a 30% higher risk of COVID-19 infection and disease progression compared with nonusers^{28,29}. Suppression of gene activity involved in immune and inflammatory responses in nasal epithelial cells has been documented in individuals who vape³⁰. Likewise, smoking and/or vaping increase oxidative stress and pulmonary inflammatory responses, making smokers and vapers more susceptible to bacterial and viral infections³¹.

Vaping has increasingly been associated with the development and exacerbation of pulmonary diseases. EVALI (e-cigarette or vaping product use – associated lung injury) is characterized by acute lung injury, acute fibrinous pneumonitis, diffuse alveolar damage, or pneumonia accompanied by bronchiolitis^{32,33} and increases the risk of COVID-19 complications among vapers. Dysregulation of airway lipids in users of electronic nicotine delivery systems (ENDS) may render them more susceptible to SARS-CoV-2 infection³⁴. Therefore, it is important to strengthen the evidence that vaping directly affects the immune system and harms health³⁵.

Furthermore, Gaiha et al. identified an association between youth smoking, electronic cigarette use, and COVID-19. They reported that vaping and dual use of conventional and electronic cigarettes – the most common pattern of use – were associated with a greater likelihood of being diagnosed with COVID-19 and experiencing

symptoms. A COVID-19 diagnosis was 5 times more likely among those who had ever used electronic cigarettes and 6.8 times more likely among dual users in the past 30 days. In addition, symptoms were 4.7 times more likely among dual users in the past 30 days (Table 1)³⁶.

Conclusions

Identifying factors associated with a higher incidence of infection and the development of severe forms of disease is essential for designing specific public health programs and strategies. These actions help reduce both incidence and poor prognosis, as well as associated mortality. Smoking, recognized as a disease with multiple harmful effects on health, should be considered a relevant risk factor in the context of COVID-19, as it increases the likelihood of complications and adverse outcomes.

Funding

This work did not receive any funding.

Conflicts of interest

The authors declared no conflicts of interest whatsoever.

Ethical considerations

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this research.

Confidentiality, informed consent, and ethical approval. The study does not involve personal patient data and does not require ethical approval. SAGER guidelines do not apply.

Declaration on the use of artificial intelligence. The authors declare that they did not use any type of generative artificial intelligence in drafting this manuscript.

References

- Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: a systematic review and meta-analysis. *Postgrad Med.* 2020;132(8):749-55. <https://doi.org/10.1080/00325481.2020.1786964>.
- Ganaza-Domingues KLT, Ramos-Milare AC, FHF, Lera-Nonose DSSL, Brustolin AA, De Oliveira LF, Rosa JS, et al. Effect of comorbidities on the mortality of patients with COVID-19: A systematic review of reviews and meta-analyses. *Rev Med Virol.* 2025;35(2):e70024. <https://doi.org/10.1002/rmv.70024>.
- Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. *J Infect.* 2020;81(2):e16-e25. <https://doi.org/10.1016/j.jinf.2020.04.021>.
- Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J Med Virol.* 2020;92(10):1875-83. <https://doi.org/10.1002/jmv.26050>.
- Fitero A, Bungau SG, Tit DM, Endres L, Khan SA, Bungau AF, et al. Comorbidities, associated diseases, and risk assessment in COVID-19—A systematic review. *Int J Clin Pract.* 2022;2022:1571826. <https://doi.org/10.1155/2022/1571826>.
- Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol.* 2020;35(12):1123-38. <https://doi.org/10.1007/s10654-020-00698-1>.
- Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020;94:91-5. <https://doi.org/10.1016/j.ijid.2020.03.017>.
- Yang J, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: An updated systematic review and meta-analysis. *J Med Virol.* 2021;93(5):2662-74. <https://doi.org/10.1002/jmv.26677>.
- Sumsuzzman DMd, Ye Y, Wang Z, Pandey A, Langley JM, Galvani AP, et al. Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis. *BMC Infect Dis.* 2025;25(1):215. <https://doi.org/10.1186/s12879-025-10610-5>.
- Serpa GL, Renton ND, Lee N, Crane MJ, Jamieson AM. Electronic nicotine delivery system aerosol-induced cell death and dysfunction in macrophages and lung epithelial cells. *Am J Respir Cell Mol Biol.* 2020;63(3):306-16. <https://doi.org/10.1165/rmb.2019-0200oc>.
- Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. *JAMA Intern Med.* 2023;183(6):566. <https://doi.org/10.1001/jamainternmed.2023.0750>.
- Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. *Int J Public Health.* 2020;65(5):533-46. <https://doi.org/10.1007/s00038-020-01390-7>.
- Földi M, Farkas N, Kiss S, Zádori N, Váncsa S, Szakó L, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis. *Obes Rev.* 2020;21(10):e13095. <https://doi.org/10.1111/obr.13095>.
- Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. *Semin Thromb Hemost.* 2020;46(07):763-71. <https://doi.org/10.1055/s-0040-1715456>.
- Lin L, Wang X, Ren J, Sun Y, Yu R, Li K, et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. *BMJ Open.* 2020;10(11):e042573. [doi:10.1136/bmjopen-2020-042573](https://doi.org/10.1136/bmjopen-2020-042573).
- Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Int Urol Nephrol.* 2020;52(6):1193-4. <https://doi.org/10.1136/bmjopen-2020-042573>.
- Sharma P, Zeki AA. Does vaping increase susceptibility to COVID-19? *Am J Respir Crit Care Med.* 2020;202(7):1055-6. <https://doi.org/10.1164/rccm.202005-2103le>.
- Franzen KF, Willig J, Cayo Talavera S, Meusel M, Sayk F, Reppel M, et al. E-cigarettes and cigarettes worsen peripheral and central hemodynamics as well as arterial stiffness: a randomized, double-blinded pilot study. *Vasc Med.* 2018;23(5):419-25. <https://doi.org/10.1177/1358866318779694>.
- Duncan MS, Freiberg MS, Greevy RA, Kundu S, Vasani RS, Tindle HA. Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease. *JAMA.* 2019;322(7):642-50. <https://doi.org/10.1001/jama.2019.10298>.
- Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies. *Eur J Prev Cardiol.* 2019;26(3):279-88. <https://doi.org/10.1177/2047487318806658>.
- Vidyasagan AL, Siddiqi K, Kanaan M. Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis. *Eur J Prev Cardiol.* 2016;23(18):1970-81. <https://doi.org/10.1177/2047487316654026>.
- Inoue-Choi M, Hartge P, Park Y, Abnet CC, Freedman ND. Association between reductions of number of cigarettes smoked per day and mortality among older adults in the United States. *Am J Epidemiol.* 2019;188(2):363-71. <https://doi.org/10.1093/aje/kwy227>.
- Chang JT, Anic GM, Rostron BL, Tanwar M, Chang CM. Cigarette smoking reduction and health risks: A systematic review and meta-analysis. *Nicotine Tob Res.* 2021;23(4):635-42. <https://doi.org/10.1093/ntr/ntaa156>.
- Bowsher R, Marczylo TH, Gooch K, Bailey A, Wright MD, Marczylo EL. Smoking and vaping alter genes related to mechanisms of SARS-CoV-2 susceptibility and severity: a systematic review and meta-analysis. *Eur Respir J.* 2024;64(1):2400133. <https://doi.org/10.1183/13993003.00133-2024>.
- Bhalla V, Blish CA, South AM. A historical perspective on ACE2 in the COVID-19 era. *J Hum Hypertens.* 2021;35(10):935-9. <https://doi.org/10.1038/s41371-020-00459-3>.

26. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). *J Clin Med.* 2020;9(3):841. <https://doi.org/10.3390/jcm9030841>.
27. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry.* 2021;26(1):30-9. <https://doi.org/10.1038/s41380-020-00880-7> Erratum in: *Mol Psychiatry.* 2021; 26(1):40. doi: 10.1038/s41380-020-00895-0.
28. Grammatopoulos T, Yeoh E, El-Haddad N, Carson-Chahhoud K, Sitas F. Dual tobacco smoking, electronic cigarette use and COVID-19 outcomes. *Eur J Intern Med.* 2024;128:156-7. <https://doi.org/10.1016/j.ejim.2024.05.027>.
29. Scala M, Lugo A, Mosconi G, Zambon A, Odone A, Smits L, et al. The role of novel nicotine-containing products on SARS-CoV-2 infection and COVID-19 progression. *Eur J Intern Med.* 2024;121:134-5. <https://doi.org/10.1016/j.ejim.2023.12.025>.
30. Martin EM, Clapp PW, Rebuli ME, Pawlak EA, Glista-Baker E, Benowitz NL, et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. *Am J Physiol Lung Cell Mol Physiol.* 2016;311(1):L135-L144. <https://doi.org/10.1152/ajplung.00170.2016>.
31. Muthumalage T, Lamb T, Friedman MR, Rahman I. E-cigarette flavored pods induce inflammation, epithelial barrier dysfunction, and DNA damage in lung epithelial cells and monocytes. *Sci Rep.* 2019;9(1):19035. <https://doi.org/10.1038/s41598-019-51643-6>.
32. Fryman C, Lou B, Weber AG, Steinberg HN, Khanijo S, Iakovou A, et al. Acute respiratory failure associated with vaping. *Chest.* 2020;157(3):e63-e68. <https://doi.org/10.1016/j.chest.2019.10.057>.
33. Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde MW, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin – Final report. *N Engl J Med.* 2020;382(10):903-16. <https://doi.org/10.1056/nejmoa1911614>.
34. Kaur G, Lungarella G, Rahman I. SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. *J Inflamm (Lond).* 2020;17(1):21. <https://doi.org/10.1186/s12950-020-00250-8>.
35. Stratton K, Kwan LY, Eaton DL, editors. *Public Health Consequences of E-Cigarettes* [Internet]. Washington, D.C.: National Academies Press; 2018 [citado 31 ene 2023]. Available from: <https://www.nap.edu/catalog/24952>.
36. Gaiha SM, Cheng J, Halpern-Felsher B. Association between youth smoking, electronic cigarette use, and COVID-19. *J Adolesc Health.* 2020;67(4):519-23. <https://doi.org/10.1016/j.jadohealth.2020.07.002>.